Trump fetal tissue ethics board urges rejection of nearly all research proposals
By Amy Goldstein,
The Washington Post
| 08. 18. 2020
A new advisory board, created to review the ethics of proposed fetal tissue research grants, is urging the Trump administration to block government funding for nearly all of the applications — essentially seeking to ban support for most such scientific work.
The recommendation that the National Institutes of Health withhold funds from all but one of a slate of 14 research proposals means that Health and Human Services Secretary Alex Azar, who has the final say, would need to buck the will of a board he convened — and of social conservatives crucial to President Trump’s political base — for the projects to get federal support.
The board sent its advice in a report to HHS on Tuesday, less than three weeks after the announcement of its members, two-thirds of whom are outspoken opponents of abortion, fetal tissue research or both. The group has operated in secrecy, with even its own members unaware of who else was in it until the end of July, when it held a single, day-long virtual meeting, most of it closed to the public...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...